A detailed history of Waterfront Wealth Inc. transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Waterfront Wealth Inc. holds 860,613 shares of AMRN stock, worth $542,186. This represents 0.17% of its overall portfolio holdings.

Number of Shares
860,613
Previous 525,644 63.73%
Holding current value
$542,186
Previous $467,000 26.98%
% of portfolio
0.17%
Previous 0.13%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$0.63 - $1.07 $211,030 - $358,416
334,969 Added 63.73%
860,613 $593,000
Q1 2024

May 13, 2024

BUY
$0.82 - $1.35 $113,905 - $187,527
138,909 Added 35.92%
525,644 $467,000
Q4 2023

Jan 31, 2024

BUY
$0.66 - $0.91 $38,901 - $53,637
58,942 Added 17.98%
386,735 $336,000
Q3 2023

Nov 09, 2023

BUY
$0.85 - $1.43 $34,014 - $57,224
40,017 Added 13.91%
327,793 $301,000
Q2 2023

Jul 28, 2023

BUY
$1.12 - $1.49 $117,244 - $155,977
104,683 Added 57.17%
287,776 $342,000
Q1 2023

Apr 19, 2023

SELL
$1.19 - $2.19 $2,183 - $4,018
-1,835 Reduced 0.99%
183,093 $274,000
Q4 2022

Jan 30, 2023

SELL
$1.07 - $1.34 $22,632 - $28,343
-21,152 Reduced 10.26%
184,928 $223,000
Q3 2022

Nov 01, 2022

SELL
$1.09 - $1.67 $1,378 - $2,112
-1,265 Reduced 0.61%
206,080 $241,000
Q2 2022

Jul 25, 2022

BUY
$1.13 - $3.69 $98,625 - $322,059
87,279 Added 72.69%
207,345 $309,000
Q1 2022

May 13, 2022

BUY
$2.85 - $3.73 $283,369 - $370,866
99,428 Added 481.77%
120,066 $418,000
Q4 2021

Feb 14, 2022

SELL
$3.24 - $5.18 $8,200 - $13,110
-2,531 Reduced 10.92%
20,638 $70,000
Q3 2021

Nov 02, 2021

SELL
$3.94 - $5.84 $8,214 - $12,176
-2,085 Reduced 8.26%
23,169 $118,000
Q2 2021

Aug 04, 2021

BUY
$4.26 - $6.5 $107,582 - $164,151
25,254 New
25,254 $111,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $254M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Waterfront Wealth Inc. Portfolio

Follow Waterfront Wealth Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Waterfront Wealth Inc., based on Form 13F filings with the SEC.

News

Stay updated on Waterfront Wealth Inc. with notifications on news.